Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world experience in the first-line treatment of Acute Myeloid Leukemia with ven-aza: Optimizing venetoclax exposure for better outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMarta Isabel Pereira

Discussion

Loading...

Member takes

Overview

Observational analysis found that managing neutropenia improved treatment outcomes in acute myeloid leukemia patients receiving venetoclax, indicating a need for effective support protocols.

Key Points

  • Median overall survival reached 21.4 months for acute myeloid leukemia patients with careful management.
  • 60% of first cycles experienced neutropenia, impacting treatment effectiveness and leading to delays.
  • Treatment strategies focused on drug-drug interactions and aimed at reducing hematologic toxicity resulted in better outcomes.
  • Supportive care with G-CSF during treatment was essential for optimizing the venetoclax exposure.

Cite This Study

Marta Isabel Pereira (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d33fhttps://doi.org/10.1182/blood-2025-6971
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  2. 2Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study2025 · 1 citations
  3. 3Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  4. 4Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study2025 · 2 citations
  5. 5High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025